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doi:10.1016/j.bjps.2007.11.019Summary Background: Composite tissue allotransplantation of hand, facial and other tissues
is now a clinical reality. The terminology, treatment principles, drug combinations, dosage
schedules and mechanisms of the immunosuppression medications on which contemporary
transplant surgery is based are unfamiliar to plastic surgeons and most healthcare providers
outside the field of transplantation medicine. With this in mind, the purpose of this manuscript
is to provide plastic surgeons with a comprehensive and understandable review of key immu-
nological principles relevant to composite tissue allotransplantation.
Methods: We present an overview of the immunological basis of composite tissue allotrans-
plantation aimed at the plastic surgery readership, based on our own experience plus manu-
scripts sourced from MEDLINE, EMBASE, text books, ancient manuscripts and illustrations.
Results: In this manuscript we provide the reader with a brief history of composite tissue
allotransplantation (CTA), a concise description of the immunological terminology, treatment
approaches, risks associated with immunosuppressive therapy, risk acceptance, and current
research avenues relating to contemporary CTA.
Conclusion: Today, as transplant and reconstructive surgeons join forces to move hand and
facial tissue allotransplantation into the clinical arena, it is important that plastic surgeons852 0167; fax: þ1 502 852 1256.
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482 I.S. Whitaker et al.have an understanding of the major immunological principles upon which this new treatment is
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Elsevier Ltd. All rights reserved.Composite tissue allotransplantation (CTA) of hand and
facial tissues is now a clinical reality. To date, 20 in-
dividuals have received seven double hand, 12 single hand
and one thumb transplant worldwide. Several of these
cases are more than 8 years post transplant and only two
graft failures have been reported, one due to noncompli-
ance1 and the other due to unclear aetiology2 (Table 1).
Overall the functional outcomes and patient satisfaction
have been reported to be good.2 In addition, four cases of
head and neck allotransplantation have been reported,
two in China3 and two in France.4e7
The microsurgical techniques required to successfully
transplant hand and facial tissues are well established and
are used in daily practice by the plastic surgery community
worldwide. The immunosuppression medications used to
prevent tissue rejection in these cases are the same as
those used in tens of thousands of solid organ transplant
recipients and have been extensively studied for many
years. The psychosocial and ethical issues associated with
these new procedures are being developed as new clinical
cases are being performed and followed.
Some of the greatest advancements in the fields of
plastic and transplant surgery have been achieved through
a close collaboration between plastic and transplant sur-
geons. Over the past five to six decades advances in the
field of transplant immunology have transformed solid
organ transplantation into standard care, with excellent
short term results in kidney, heart, lung, liver and pancreas
transplantation.8 Most of these advancements have oc-
curred through a better understanding of how the immune
system works and as a result the development of more
effective and less toxic drugs to suppress it. As with all mul-
tidisciplinary endeavours, each specialty brings with it its
own language and terminology. In composite tissue allo-
transplantation (CTA) the immunologic principles of graft
rejection and failure as well as the mechanism of action,
routine regimens, dosages and toxicities of the drugs used
to manipulate the immune system are far removed from
the knowledge base of the general plastic surgeon.
Today, as the fields of reconstructive and transplant
surgery again join forces to introduce and move hand and
facial tissue allotransplantation into the clinical arena, it is
important that surgeons in both disciplines have a working
knowledge of the relevant scientific and technical princi-
ples in their respective fields. With this in mind, this
manuscript provides plastic surgeons with a comprehensive
and understandable review of some of the key immuno-
logical principles relevant in CTA. We accomplish this by
providing the reader a brief history of CTA, current
treatment approaches, risks associated with immunother-
apy, and current avenues of research in CTA. A timeline
with the history of CTA, illustrations of drug mechanisms
and toxicity, a listing of hand and face transplants
performed to date and a glossary of terminology (italicisedwords throughout the text appear in the glossary) are also
provided to make this review more comprehensible and
useful to the reader.
The history of composite tissue
allotransplantation (see timeline, Fig. 1)
‘The more sand that has escaped from the hourglass of
our life, the clearer we should see through it.’9
Jean Paul
A brief history of CTA
Pharmacological treatment to facilitate graft survival was
described as early as the 5th Century BC.10 In 348 AD ‘The
legend of the black leg’ (Leggenda Aurea) is the tale of
twin brothers Cosmas and Damian who replaced the dis-
eased leg of a sleeping man with that of a recently deceased
Ethiopian Moor11 and is credited with being the first known
description of a CTA. During the Renaissance in Bologna,
Italy, Gaspare Tagliacozzi, (1547e1599) described auto-
transplanting tissue from the arm to reconstruct a nose,
and allotransplantation of the nose from a slave to his
master. While the former procedure was reported to be
successful, the latter one failed. Tagliacozzi described the
problems he encountered with transplanting tissues from
one individual to another in his 1596, ‘De Curtorum Chirur-
gia per Insitionem’, where he writes ‘The singular character
of the individual entirely dissuades us from attempting this
work on another person. For such is the force and power of
individuality, that if any one should believe that he could
achieve even the least part of the operation, we consider
him plainly superstitious and badly grounded in physical
science’.
Over the next century, several reports of tissue trans-
plants appeared periodically in the literature. However, the
first substantiated short term successful allotransplant of
note was that of sheep skin reported by Bunger in 1804.12
From this time almost 100 years passed until Alexis Carrel
described successful orthotopic hind limb transplants in
dogs.13 As part of his work he developed a triangulation
suturing method for anastomosing small blood vessels. For
this and other research he was awarded the Nobel Prize
in 1912.14,15 At the same time, Guthrie described hetero-
topic allotransplantation of dog heads, with documented
good short term postoperative restoration of salivation and
eyelid function.16 Inevitably this success was short-lived and
the transplant was rejected. While these contributions laid
the foundation for the development of the microsurgical
techniques necessary for transplanting tissues, the immuno-
logical barriers were yet to be addressed.
The tragedies of war in the early 1940s provided the
impetus for investigating immunological barriers associated
Table 1 Clinical hand and facial tissue transplants performed
Type of CTA Date
performed
Location Institution Recipient
age & gender
Immunotherapy Graft survival Patient
survival
Acute
rejection
Chronic
rejection
Hand transplants
Single hand transplant Feb-1963 Guayaquil,
Ecuador
(*) 28 y/o male Cortisone/
6-mercaptopurine/
azathioprine
(AZA) &
hydrocortisone
() Rejection &
removal 3 wks
post transplant;
due to insufficient
immunosuppression
(þ) (þ) ()
Single hand transplant Sep-1998 Lyon, France Hopital Edouard
Herriot
48 y/o male FK506/MMF/
prednisolone
() Rejection &
removal of hand
2yrs 4mo post
transplant; due
to non-compliance
(þ) (þ) (þ)
Single hand transplant Jan-1999 Louisville, USA Jewish Hospital 37 y/o male FK506/MMF/
prednisolone
(þ) (þ) (þ) ()
Single hand transplant Sep-1999 Guangzhou, China Nanfang Hospital 39 y/o male FK506/MMF/
prednisolone
() Rejection &
removal of hand
1 yr 8mo post
transplant;
unknown cause
(þ) (þ) ()
Single hand transplant Jan-2000 Guangxi, China 1st Affiliated Hospital,
Guangxi Univ.
27 y/o male FK506/MMF/
prednisolone
(þ) (þ) (*) ()
Double hand transplant Jan-2000 Lyon, France Hopital Edouard
Herriot
33 y/o male FK506/MMF/
prednisolone
(þ) (þ) (þ) ()
Digital transplant Jan-2000 Yantai, China Shandong Provincial
Hospital
18 y/o male (*) (þ) (þ) (*) ()
Double hand transplant Mar-2000 Innsbruch, Austria Universitatsklinik
fur Chirurgie
45 y/o male (*) (þ) (þ) (þ) ()
Single hand transplant May-2000 Kuala-Lumpur,
Malaysia
Selayang Hospital 1 mo/o
female
None
(Identical twin)
(þ) (þ) () ()
Double hand transplant Sep-2000 Guangzhou, China Nanfang Hospital (*) (þ) (þ) (*) ()
Single hand transplant Oct-2000 Milano, Italy Milano-Bicocca
University
35 y/o male (*) (þ) (þ) (þ) ()
Double hand transplant Jan-2001 Harbin, China 1st Affiliated Hospital,
Harbin Medical Univ.
(*) (*) (þ) (þ) (*) ()
Single hand transplant Feb-2001 Louisville, USA Jewish Hospital 36 y/o male FK506/MMF/
prednisolone
(þ) (þ) (þ) ()
Single hand transplant Oct-2001 Milano, Italy Milano-Bicocca
University
(*) FK506/MMF/
prednisolone
(þ) (þ) (*) ()
Single hand transplant Jun-2002 Brussels, Belgium Erasme Univ. Hospital (*) (*) (þ) (þ) (*) ()
Single hand transplant Nov-2002 Milan, Italy Milano-Bicocca
University
(*) FK506/MMF/
prednisolone
(þ) (þ) (*) ()
Double hand transplant Feb-2003 Innsbruch, Austria Universitatsklinik
fur Chirurgie
(*) (*) (þ) (þ) (*) ()
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484 I.S. Whitaker et al.with tissue allotransplantation. A young plastic surgeon,
Thomas Gibson, was hired by the British Medical Research
Council to care for severely burned WWII pilots. While
caring for these patients, Gibson noted accelerated re-
jection of skin grafts from the same donor that were
transplanted on a second attempt at a later date.17 To
make sense of these observations, he worked with zoologist
and researcher Peter Medawar who, in animal experiments,
demonstrated that specific characteristics of the rejection
process, such as latency, memory, and specificity of graft
destruction, were the consequence of an active immune re-
sponse mounted by the recipient.17 These discoveries laid
the groundwork for the development of the field of modern
transplant immunology and consequently the development
of the immunotherapy used today to prevent allograft re-
jection. For his contributions to the field Medawar received
the Nobel Prize in medicine in 1960.
In the 1950s Joseph Murray, a plastic surgeon, studied
skin and kidney transplants in dogs and later went on to
perform the first successful human kidney transplant
between identical twins.18 The late 1950s and early 1960s
brought the discovery of agents such as azathioprine,
6-mercaptopurine and corticosteroids,19e22 which demon-
strated prolonged graft survival in solid organ transplants
in animal models. Unfortunately this same success could
not be reproduced in CTAs containing skin tissue. In 1963,
a team of surgeons in Ecuador performed the first human
hand transplant (Table 1) but inadequate immunosuppres-
sion [azathioprine (AZA) and hydrocortisone] resulted in
rejection and the hand had to be amputated 3 weeks post
transplant.23,24 The introduction of cyclosporine A (CsA),
in 1976 revolutionised the transplantation field by reducing
acute rejection rates in kidney transplant recipients from
70 to 50% and increasing short term allograft survival rates
from approximately 50 to 80% at 1 year.25e27 These positive
results in heart, kidney, pancreas and liver transplanta-
tion28,29 led to renewed attempts to transplant hind limbs
and mandible bone in small animal models and demon-
strated reduced acute rejection and prolonged survival
rates.30 In the late 1970s and early 1980s three separate
groups tested the efficacy of cyclosporine A in upper ex-
tremity transplants in primate models.31e33 Although rejec-
tion was suppressed for periods of up to 300 days, in these
experiments the highly immunogenic skin portions of trans-
planted extremities were rejected within the first few
months after transplantation. These discouraging results
together with the failed human hand transplant in Ecuador
caused reconstructive surgeons to abandon further at-
tempts to transplant hands for another decade. In the early
1990s cyclosporine-AZA steroid-based regimens were used
in several clinical CTAs to reconstruct nerves,34e36 ten-
dons,37 muscle,38 bone and joint,39 and laryngeal defects.40
More recently, additional clinical CTAs have been reported
to reconstruct abdominal wall muscle,41 tongue and
uterus.42 While the outcomes in these attempts have been
reported to be generally positive, none of these CTAs con-
tained skin and its associated appendages.
In the mid to late 1990s, with the goal of performing
human hand transplants, researchers at the University of
Louisville were evaluating a variety of approaches that
maximised immunosuppression (to prevent ‘skin’ rejection)
while minimising toxic side effects (due to the reluctance
1804
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Figure 1 Composite tissue allotransplantation history timeline.
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Figure 2 Mechanisms of actions of immunosuppressive drugs.
486 I.S. Whitaker et al.of hand surgeons to expose their amputee patients to the
relatively high risks of immunosuppression). In keeping with
these criteria several novel methods of local immuno-
suppression drug delivery were explored. These included
topical drug applications, direct drug delivery using im-
planted pumps43e47 and magnetic drug targeting (attaching
drugs to metal particles, infusing them systemically and
then using a magnet placed over the transplanted allograft
to localise the drug).48,49 Additional approaches that met
the criteria of maximal immunosuppression with minimal
toxicity were also studied: tolerance induction,50e53 low
dose immunosuppression,54 and lymph node removal.55,56
In one of these experiments investigating local drug deliv-
ery using implanted pumps in a pig forelimb CTA model,57,58
the control group consisted of animals receiving a drug reg-
imen, considered at the time, and still today, to be the best
treatment in clinical kidney transplantation (tacrolimus/
mycophenolate mofetil (MMF)/corticosteroid). In this ex-
periment the pumps (experimental group) malfunctioned,
while the limbs of the controls animals, receiving the
drug combination tacrolimus/MMF/corticosteroid orally,
unexpectedly survived for the duration of the experiment
with relatively low toxic side effects.59,60 Based on these
findings the team in Louisville applied to their hospitals’
institutional review board for approval to perform human
hand transplants. These landmark experimental findings
opened the door to performing human hand transplants,
and between 1998 and 1999, teams in Lyon (France),61
Louisville (USA)62 and Guangzhou (China) performed the
first four successful hand transplants using tacrolimus/
MMF and corticosteroid combination therapy.63 Today seven
of 20 hand transplants performed worldwide are more than
8 years post transplant and only two graft failures have
been reported, one due to noncompliance64 and the other
performed in China, due to unclear aetiology.2 Overall the
functional outcomes and patient satisfaction have been
reported to be good.2 The successful use of this tacrolimus
/MMF/corticosteroid combination therapy in hand trans-
plants has led other groups that had performed laryngeal,
bone, nerve, and more recently facial tissue allotrans-
plants,5,6,65 to use this same drug combination.
Immunotherapy approaches used in composite
tissue allotransplantation
The ultimate goal and thus the focus of transplant immu-
nology research is to effectively suppress rejection whilst
minimising toxic side effects. In clinical practice this is
achieved through a comprehensive balance of multiple
drugs and methodologies that interfere with the immune
response at various sites by blocking the formation, stim-
ulation, proliferation, and differentiation of lymphocytes
(Fig. 2). These drugs are administered immediately after
transplanting the organ or tissues (induction therapy) and
regularly thereafter ‘for life’ (maintenance therapy) and
in response to rejection episodes (treatment or rescue ther-
apy) (Table 2).
Induction therapy (Table 2)
The goal of induction therapy is to achieve immediate, pro-
found immunosuppression for approximately 2 weeks posttransplant to reduce the likelihood of immediate rejection
(within 7e14 days post transplant) and early acute rejec-
tion (within 3e6 months after the transplant). Globally, in-
duction therapy decreases the severity of the first rejection
and delays the time to first rejection while allowing time
immediately post transplant to achieve target immunosup-
pressive levels of the maintenance agents. The four primary
drugs currently used clinically for induction therapy in solid
organ transplants are: polyclonal anti-thymocyte globulins
(ATG); anti-interleukin- 2 (IL-2) receptor monoclonal anti-
bodies (Daclizumab and Basiliximab); Campath-1H and
anti-CD3 monoclonal antibodies (Table 2).66 In addition to
these drugs, donor bone marrow infusion has also been
Table 2 Immunosuppressive drugs and their associated toxicities
Therapy
type
Drug Class Toxicities/adverse effects
Hyper-
tension
Hyper-
glycaemia
Nephro-
toxicity
Hyper-
lipidaemia
Malignancy Infection Other
Induction Antithymocyte
globulin (ATG)
Polyclonal
antibody
Ø Ø Ø Ø þþ þþþ Anaphylactic
reaction,
serum sickness
Anti-interleukin-2
receptor
monoclonal
antibodies
(Daclizumab
& Basiliximab)
Monoclonal
antibody
Ø Ø Ø Ø Ø þ Anaphylactic
reaction (rare)
Anti-CD3
monoclonal
antibodies
(OKT3)
Monoclonal
antibody
Ø Ø Ø Ø þþ þþþ Anaphylactic
reaction,
pulmonary
oedema
Maintenance Tacrolimus
(FK506)
Calcineurin
inhibitor
þ þþ þþ þ þ þþ Tremor, liver
MMF
(mycophenolate
mofetil)
Anti-
proliferative
agent
Ø Ø Ø Ø þ þþ Gastric, bone
marrow
Corticosteroids Cortico-
steroid
þþ þþþ Ø þþþ Ø þþþ Osteoporosis
Treatment
or rescue
Sirolimus
(rapamycin)
TOR
inhibitor
Ø Ø Ø þþ Ø/ þþ Proteinuria,
bone marrow
Corticosteroids
(increased dosage)
See above
Tacrolimus
(increased dosage)
Antibodies
(increased dosage)
KEY: þZmild, þþZmoderate, þþþZ severe, ØZ none.
Immunology review for plastic surgeons 487tried, on an experimental basis, for induction therapy. In an
attempt to induce tolerance through microchimerism, the
team in Amiens, France, transplanted donor derived bone
marrow along with the facial tissues.4 While this approach
has been reported to induce tolerance in an animal
model67,68 its effectiveness in humans remains controver-
sial. Post transplant assessments for the presence of toler-
ance in the facial tissue recipient in this case in France have
been reported to be negative.69
It is important to note that the use of induction agents has
been stabilising primarily due to their efficacy in kidney
transplantation with steroid minimisation regimens. T-cell
depleting induction agents ATG and anti-CD3 monoclonal
antibodies (OKT3) have been associated with increased
infection and post transplant lymphoproliferative disorders
(PTLD). In addition, induction agents have significant costs
associated with their use.
Maintenance therapy (Table 2)
The goal of maintenance therapy is to reduce the immune
system’s ability to recognise and reject the foreign organ
or tissue, while limiting toxicity. As the patient progresses
further post transplant the risk of rejection is reducedand the immunosuppressive regimen is tailored to the
individual patient to provide lifelong suppression of the
immune system with minimal toxicity. The primary drug
combination used for maintenance therapy in hand and fa-
cial tissue allotransplantation is tacrolimus (FK506), myco-
phenolate mofetil (MMF ) and corticosteroids (see below).2
Treatment or rescue therapy (Table 2)
Corticosteroids are the first line of treatment in acute
rejection episodes. However, when they are unsuccessful
the same powerful antibody-based therapy used in induc-
tion is usually started. Rejection episodes have also been
successfully treated with high-dose tacrolimus and siroli-
mus (rapamycin). In hand and facial tissue allotransplanta-
tion topical corticosteroids and topical tacrolimus have
also been used successfully.2
Combination therapy
In solid organ, hand and facial tissue allotransplantation,
combinations of drugs are employed in dual, triple, or
sequentially in countless variations. Contemporary proto-
cols use a range of drugs, dosage schedules, administration
methods, and monitoring guidelines.2,66,70 In most cases
488 I.S. Whitaker et al.each of the drugs used inhibits the immune system at differ-
ent site(s). The overall effect of combining different drugs
that act by different mechanisms is that a very powerful im-
munosuppressive effect is achieved. This makes it possible
to administer low doses of each individual drug and thus re-
duce the drug-related toxicity. Due to its effectiveness in
suppressing skin rejection and relatively low toxic side ef-
fects, tacrolimus-based combination therapy has become
the immunotherapy of choice for hand and facial tissue
allotransplantation.
Tacrolimus (FK506) introduction in 1992 led to a decrease
in 1-year acute rejection rates from the previous 50% with
cyclosporine-based immunosuppression to approximately
30%.71 Tacrolimus is a macrolide antibiotic, derived from
the soil fungus Streptomyces tsukubaensis72 that prevents
T-cell activation and suppresses B-cell activation and like
cyclosporine is a calcineurin inhibitor. In vitro tacrolimus
has been shown to be 100 times more potent than cyclo-
sporine (Table 2; Fig. 2).73 It is of interest that tacrolimus
has been shown to promote nerve regeneration in small
animal models after nerve injury.74,75 These effects seem
to be related to actions of multiple neuroimmunophilin li-
gands76 and may be of particular use in instances such as
hand and facial CTA where motor and sensory function is
crucial for overall function. In fact this effect of promoting
nerve regeneration is thought to be responsible for the
‘better than expected’ early functional outcomes reported
in the clinical hand and facial tissue allotransplants per-
formed.2,4 As mentioned above, tacrolimus has also been
used clinically in the form of a topical immunosuppressant
for maintenance therapy and to reverse acute rejection
episodes in both hand and face transplantation.2,4 Topical
tacrolimus ointment is also used in the clinical setting to
treat various skin conditions such as atopic dermatitis, pso-
riasis and pyoderma gangrenosum.77e80
Mycophenolate mofetil (MMF ) introduction in 1995
resulted in the lowering of acute rejection rates.81 When
combined with tacrolimus and corticosteroid, MMF pro-
vided 1-year acute rejection rates below 20%.82e92 MMF is
an antiproliferative immunosuppressive drug that selec-
tively inhibits the rate-limiting enzyme inosine monophos-
phate dehydrogenase, required for de novo synthesis of
guanosine nucleotide. This is essential for proliferation of
T and B lymphocytes (Table 2; Fig. 2).
Corticosteroids are cytokine gene expression blockers
and, along with adrenal glucocorticoids, are the most
commonly used immunosuppression drugs. Prednisolone,
the prototype in this class, is analogous to the major endog-
enous corticosteroid, cortisol (hydrocortisone), but four
times more potent in its action. The actions are mediated
by subcellular hormone receptors that form steroid recep-
tor complexes, bind to DNA and affect the expression of
genes driving protein synthesis and cellular processes
(Table 2; Fig. 2).
Risks associated with immunotherapy
Immunosuppression-associated risks pose perhaps the great-
est barrier to performing routine hand and facial tissue
allotransplantation. The risks associated with the immuno-
suppressive drugs currently used in hand and facial tissue
allotransplantation are well known, having been studied intens of thousands of organ transplant recipients over the
past 15 years and more recently in hand (8 years) and facial
tissue (1 year) transplant recipients. There are currently no
objective means for evaluating the overall state of immu-
nosuppression. As a result, clinical manifestations of under-
immunosuppression (acute rejection) and over-immunosup-
pression (infection and malignancy) provide only general
indicators of the degree to which the immune system is
suppressed. In the following section we divide the discus-
sion of immunosuppression-associated risks into three parts;
risks of rejection, risks associated with immunosuppression
and finally the perception of risk by affected populations.
Risks of rejection
Under-immunosuppression can lead to acute rejection. In
human hand transplant recipients acute rejection rates
were recently reported to be 67% at 1 year. In these cases
all acute rejection episodes were successfully reversed
regardless of the anti-rejection therapy used.2 These high
acute rejection rates observed in hand transplants (com-
pared to kidney transplants) may be explained, in part,
by the greater immunogenicity of skin tissue.1,64,93,94 In
solid organ transplantation high acute rejection rates are
often associated with high incidence of chronic rejection
(see below) and low organ survival rates. However, this
has not been the experience in hand transplantation. De-
spite the relatively high acute rejection rates observed in
hand transplant recipients, survival rates have been high.
This may be due to early detection (made possible by direct
visual inspection of the skin) allowing immediate treatment
and reversal of acute rejection episodes.
Chronic rejection is the most important cause of late
graft loss in solid organ transplantation. While the mecha-
nisms of chronic rejection have not been well defined,
experience in solid organ transplantation indicates that
high occurrence of acute rejection episodes coincides
with higher incidence of chronic rejection.95,96 This has
not been observed in human hand transplants. In one out
of 20 hand transplants performed, clinical and histological
characterisation of what was believed to be chronic (cutane-
ous) rejection was reported. In this single case, more than 2
years post transplant, the patient stopped taking his immu-
nosuppression medication which led to graft failure and the
hand had to be surgically removed.1,64 This relatively low oc-
currence of chronic rejection may be attributable to three
main factors: (1) follow up is relatively short; (2) CTAs do
not appear to be subject to vascular and parenchymal toxic-
ity of immunosuppressive medication, as are kidney allo-
grafts; and (3) early recognition enabling early treatment
and reversal of acute rejection. Additional evaluations of
chronic rejection in human hand and facial tissue allotrans-
plantation are needed to better define its risk and influence
on long-term allograft survival.
Graft loss occurs when all attempts to reverse rejection
fail and the decision is made to discontinue the immunosup-
pression medications. Graft loss has been reported in two
out of 20 human hand transplants, one mentioned above,
due to medication noncompliance at 2 years and 4 months
post transplant64 and the other due to uncertain aetiology
(Table 1). The graft may also be ‘lost’ if a decision is
made to surgically remove a viable graft in the presence
Immunology review for plastic surgeons 489of drug toxicity, infection or malignancy, when saving the
patient’s life is clearly more important than saving the allo-
transplant. This situation has not been reported in any of
the hand or face transplants performed to date.
Risks associated with immunosuppression in CTA
The primary complications associated with immunosup-
pressive therapy in solid organ transplantation are due to
over-immunosuppression. These risks can be categorised
into immunologic and nonimmunologic. The immunologic
complications include malignancies, cardiovascular-related
disease, nephrotoxicity, gastrointestinal adverse effects,
diabetes and infection.
In the hand and face transplants performed to date,
infection has been the main complication reported.2 Of
these, bacterial infections occurred at a rate of 12% (two in-
fections: Clostridium difficile enteritis and Staphylococcus
aureus osteitis), fungal infections occurred in 28% (all cuta-
neous mycoses without invasive disease) and viral infection
in 34% of cases. Only 6% of patients experienced cutaneous
herpes simplex infections. None of these infections resulted
in graft or patient loss.2 Post transplantation bone disease
was reported in a single case of avascular necrosis of thehip.2
Nonimmunologic risks
Nonimmunologic risks are primarily due to adverse effects
of immunosuppressive and prophylactic agents used in
transplant recipients. Immunosuppressive agents may in-
crease cardiovascular risk97 by affecting cholesterol levels,
triglycerides,98 blood pressure,99 renal dysfunction and
post transplant diabetes mellitus.98,100 While post trans-
plant diabetes mellitus has not been reported, transient
hyperglycaemia occurred in 50% of the hand transplant
recipients, primarily while receiving high corticosteroid
doses early after transplantation.2
Noncompliance was a problem in one of 20 patients and
this could possibly have been avoided had a more careful
pre-transplant psychosocial screening assessment been
performed. Overall, with a post transplant follow up of 8
years in human hand transplantation, the incidence of graft
failure and complications has been low while functional and
aesthetic recovery has been described as good (Table 1).
Immunosuppressive risk acceptance in CTA
Ultimately patients will decide whether the risks of immu-
nosuppression justify the benefits of hand and face
allotransplantation. In a study that questioned facially
disfigured individuals (who could benefit from a face trans-
plant), kidney transplant recipients (who live with the risks
of immunosuppression), and healthy controls on the amount
of risk they would accept to receive several types of non-
life-saving transplant procedures, all respondents would
accept the most risk to receive a face transplant. When
provided a list of 20 potential immunosuppressive side
effects, 77% of facially disfigured respondents, 93% of
kidney transplant recipients, and 86% of the controls would
be willing to undergo face transplantation.101 When asked if
they would opt for face transplantation if the possibility ofrejection within 1 year was 50%, 71% of facially disfigured
persons, 88% of organ transplant recipients, and 87% of
non-affected individuals said ‘yes’.101 These findings indi-
cate that both affected and non-affected individuals view
the risks of a face transplant as more acceptable than other
non-life-saving treatments including kidney transplantation,
a standard treatment for which there is no comparable
debate.
Current and future avenues of research in CTA
The ideal immunosuppressive strategy would be a combina-
tion of agents that are selective and specific in function,
synergistically active for maximal effectiveness, free of
toxic reactions, easy to administer, and inexpensive. To
date, no ideal immunosuppressive drug has been devel-
oped. Continued research has ensured the introduction of
more effective and less toxic immunosuppressant options.
Despite this effort, currently available agents still fall short
of being ideal. Several promising drugs in development
include a once daily formulation of tacrolimus (Prograf);
LEA, a co-stimulatory blocking agent; and ISATX247, a small
molecule calcineurin inhibitor with a potentially improved
toxicity profile.
Immunologic tolerance, introduced by Medawar as ‘ac-
tively acquired tolerance’ in the early 1950s, could poten-
tially eliminate the need for immunosuppressant drugs.
This approach would minimise or potentially even eliminate
the need for long-term immunosuppression and the risks
associated with it.
While tolerance has been demonstrated using a variety
of different protocols in animal models,102,103 to date,
widespread clinical applicability of these protocols has
been impeded due to the toxicity of the methods required
to induce tolerance and the lack of successful studies in
large animals.104,105
Hand and facial tissue composite tissue allotransplanta-
tion is now a clinical reality with encouraging early resul-
ts.2e7 As in the past, this advancement has been achieved
through close collaboration with transplant immunologists.
The development of new drugs designed to maximally and
selectively suppress the immune system, while at the same
time causing minimal toxic side effects, has made CTA a via-
ble reconstructive treatment option. In this paper we have
reviewed key terminology, drug combinations, mechanisms
of immunosuppression and the risks associated with CTA.
Plastic surgeons play a central role in treating facially dis-
figured individuals and will thus lead the development of
these new reconstructive treatments. Accordingly, it is
important that they be informed of the issues discussed in
this manuscript. Informed consent, taking into account
both individual and process factors, is critical when one dis-
cusses radical new procedures with patients.106 We hope
this paper will serve as a reference for the readership to
consider and discuss CTA with their colleagues and patients.References
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Acute rejection: Rejection occurring within the first three months
post transplant. Mediated by the primary activation of T-cellsresulting in platelet aggregation, fibrinoid necrosis of media
arteries, and vascular obstruction.
Azathioprine (AZA): The imidazole derivative of 6-MP which is
cytotoxic. AZA is converted in the liver to 6-MP which in turn
resembles inosine monophosphate and causes fraudulent
feedback inhibition of the early enzymes catalysing the cellular
synthesis of DNA.
Calcineurin inhibitor: These drugs exert their effects through
regulation of cytokine production. Cyclosporin A was the pro-
totype in this class, used since the 1950s, and in the mid- to
late-1980s tacrolimus (FK506) was introduced into clinical
practice.
Chronic rejection: Rejection occurring months to years post trans-
plant. Graft injury by immunological and non immunological
factors.
Combination therapy: Combinations of drugs are used, with the
goal of inhibiting different aspects of the immune response.
The overall effect of this approach is a very powerful anti-rejec-
tion effect thus making it possible to administer low doses of
each individual drug.
Cyclosporin: Cyclosporin A is a fungal metabolite from Tolypocla-
dium inflatum gams. Its immunosuppressive action is due to
the suppression of IL-2 production by T-cells.
Hyperacute rejection: Rejection occurring in the first few minutes
post transplant. It is an antibody-mediated process via MHC.
Damage to endothelial cells and small arterioles leads to micro-
vascular blockage and graft failure.
Induction therapy: Silencing of the immune system for approxi-
mately 2 weeks post transplant to reduce the likelihood of
acute rejection.
Maintenance therapy: Intermediate term (>2 weeks post induc-
tion) reduction of the immune system’s ability to recognise
and reject foreign tissue, reducing the risk of chronic rejec-
tion, whilst allowing sufficient remaining host defences to de-
fend against infections and reduce the likelihood of malignant
transformation.
Mixed chimerism: Refers to the coexistence of donor and recipient
haematopoietic cells, with donor representation that can be
detected by non-PCR-based techniques. The state of mixed
chimerism can also be referred to as macrochimerism.
Microchimerism: The presence of two genetically distinct and
separately derived populations of cells, one population being
at a low concentration, in the same individual or an organ
such as the bone marrow.
Neuroimmunophilin ligands: Neuroimmunophilin ligands are a class
of compounds that hold great promise for the treatment of
nerve injuries and neurological disease which act via unique
receptors to afford neuroprotective and neuroregenerative
properties via different mechanisms.
Tolerance: Donor-specific unresponsiveness without the need for
combined immunosuppression - A situation where the recipient
does not mount an immune response against the allograft but
remains fully immunocompetent.
Treatment: Specific agents used to treat or suppress episodes of
acute rejection.
